Vitreous biomarkers in diabetic retinopathy: A systematic review and meta-analysis

Journal of Diabetes and its Complications

Volumn 28, Issue 3, 2014, Pages 419-425

  McAuley, Annie K ^a   Sanfilippo, Paul G ^a,b   Hewitt, Alex W ^a,b   Liang, Helena ^a   Lamoureux, Ecosse ^a,e,f   Wang, Jie Jin ^a,c   Connell, Paul P ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

EPO; HGF; IL 6; IL 8; KEGG pathway; Macular edema; Proliferative retinopathy; VEGF; Vitrectomy

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA;

CELL THERAPY; CLINICAL TRIAL; DIABETIC RETINOPATHY; HUMAN; META ANALYSIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VITREOUS BODY; METABOLISM;

BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; HUMANS; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TRANSFORMING GROWTH FACTOR BETA; VITREOUS BODY;

EID: 84899411337     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2013.09.010     Document Type: Article

References (58)

1. L.P. Aiello et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders New England Journal of Medicine 331 22 1994 1480 1487
2. W.K. Alderton, C.E. Cooper, and R.G. Knowles Nitric oxide synthases: Structure, function and inhibition Biochemical Journal 357 Pt 3 2001 593 615
3. J.F. Arevalo et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy British Journal of Ophthalmology 92 2 2008 213 216
4. J.W. Bainbridge et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 Gene Therapy 9 5 2002 320 326
5. B.B. Banu Turgut Ozturk, K. Hurkan, O. Mehmet, K. Umit, and G. Kemal Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness Molecular Vision 15 2009 1906 1914
6. F. Barutta et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy Diabetes 60 9 2011 2386 2396
7. B.P. Nicholson, and A.P. Schachat A review of clinical trials of anti-VEGF agents for diabetic retinopathy Graefes Archive for Clinical and Experimental Ophthalmology 248 7 2010 915 930
8. J. Cai, and M. Boulton The pathogenesis of diabetic retinopathy: Old concepts and new questions Eye (London, England) 16 3 2002 242 260
9. A.M. Carneiro et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab Ophthalmologica 225 4 2011 211 221
10. Y.H. Chen et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms Diabetes 56 6 2007 1559 1568
11. P. Connell et al. Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells Endothelium 14 1 2007 17 24
12. R. DerSimonian, and R. Kacker Random-effects model for meta-analysis of clinical trials: An update Contemporary Clinical Trials 28 2 2007 105 114
13. D.H. Dobrogowska et al. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor Journal of Neurocytology 27 3 1998 163 173
14. N.M. Elsherbiny, and M.M. Al-Gayyar Adenosine receptors: New therapeutic targets for inflammation in diabetic nephropathy Inflammation & Allergy Drug Targets 12 3 2013 153 161
15. A. Ergul Endothelin-1 and diabetic complications: Focus on the vasculature Pharmacological Research 63 6 2011 477 482
16. T.J. Giove et al. Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy Molecular Vision 15 2009 2249 2258
17. Y. Hattori et al. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells Metabolism 40 2 1991 165 169
18. V. Haurigot et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy PLoS One 7 7 2012 e41511
19. K.K. Hirschi, S.A. Rohovsky, and P.A. D'Amore PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10 T1/2 cells and their differentiation to a smooth muscle fate Journal of Cell Biology 141 3 1998 805 814
20. R.R. Holman et al. 10-year follow-up of intensive glucose control in type 2 diabetes New England Journal of Medicine 359 15 2008 1577 1589
21. W. Jelkmann Erythropoietin: Structure, control of production, and function Physiological Reviews 72 2 1992 449 489
22. N.M.C. Jo, M. Ju, E. Cheung, J. Bradley, K. Nishijima, and G.S. Robinson et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization American Journal of Pathology 168 6 2006 2036 2053
23. A.M. Joussen et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations Molecular Vision 15 2009 1418 1428
24. A.C. Jürgen Schellera, S.-A. Dirk, and R.-J. Stefan The pro- and anti-inflammatory properties of the cytokine interleukin-6 Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813 5 2011 878 888
25. P. Kaiser Antivascular endothelial growth factor agents and their development: Therapeutic implications in ocular disesases American Journal Ophthalmol 142 2006 660 668
26. T.S. Kern, and A.J. Barber Retinal ganglion cells in diabetes Journal of Physiology 586 Pt 18 2008 4401 4408
27. L.Z.I. Kozlowski, P. Tokajuk, and M.Z. Wojtukiewicz Concentration of interleukin-6 (Il-6), interleukin-8 (Il-8) and interleukin-10 (Il-10)in blood serum of breast cancer patients Roczniki Akademii Medycznej w Biaymstoku 48 2003 82 84
28. R. Longeras et al. A PEDF-derived peptide inhibits retinal neovascularization and blocks mobilization of bone marrow-derived endothelial progenitor cells Experimental Diabetes Research 2012 2011 518426
29. A.K. McAuley, P.G. Sanfilippo, P.P. Connell, J.J. Wang, M. Dirani, and E. Lamoureux et al. Circulating biomarkers of diabetic retinopathy: A systematic review and meta-analysis Diabetes Management 2 2 2012 157 169
30. T.A. Mendel et al. Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy PLoS One 8 5 2013 e65691
31. D. Moher et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement PLoS Medicine 6 7 2009 e1000097
32. J. Mones Inhibiting VEGF and PDGF to treat AMD Review of Ophthalmology 18 9 2011 56 61
33. K. Mori et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization Investigative Ophthalmology & Visual Science 43 6 2002 1994 2000
34. N. Murakoshi et al. Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice Circulation 106 15 2002 1991 1998
35. P. Nagarkatti et al. Cannabinoids as novel anti-inflammatory drugs Future Medicinal Chemistry 1 7 2009 1333 1349
36. C. Napoli et al. Effects of nitric oxide on cell proliferation: Novel insights Journal of the American College of Cardiology 62 2 2013 89 96
37. K. Park et al. Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization American Journal of Pathology 178 2 2011 688 698
38. T. Qaum et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes Investigative Ophthalmology & Visual Science 42 10 2001 2408 2413
39. C. Romagnoli et al. Erythropoietin and retinopathy of prematurity Early Human Development 87 Suppl 1 2011 S39 S42
40. J.B. Saaddine et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050 Archives of Ophthalmology 126 12 2008 1740 1747
41. K. Sachidanandam et al. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes Diabetes 56 11 2007 2753 2758
42. F.A. Scappaticci et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab Journal of the National Cancer Institute 99 16 2007 1232 1239
43. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Research and Clinical Practice 87 1 2010 4 14
44. R. Simo, and C. Hernandez Intravitreous anti-VEGF for diabetic retinopathy: hope and fears for a new therapeutic strategy Diabetologia 51 9 2008 1574 1580
45. L.E. Smith et al. Oxygen-induced retinopathy in the mouse Investigative Ophthalmology & Visual Science 35 1 1994 101 111
46. B.T.B. Sripa, E. Mairiang, T. Laha, S. Kaewkes, P. Sithithaworn, and M.V. Periago et al. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini PLoS Neglected Tropical Diseases 6 5 2012 e1654
47. V. Stellmach et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor Proceedings of the National Academy of Sciences of the United States of America 98 5 2001 2593 2597
48. I.M. Stratton et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis Diabetologia 44 2 2001 156 163
49. P. Ten Dijke, and H.M. Arthur Extracellular control of TGFbeta signalling in vascular development and disease Nature Reviews. Molecular Cell Biology 8 11 2007 857 869
50. O.M. Tepper et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures Circulation 106 22 2002 2781 2786
51. T.E. Walshe et al. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature PLoS One 4 4 2009 e5149
52. Q. Wang, S. Gorbey, F. Pfister, S. Höger, A. Dorn-Beineke, and K. Krügel et al. Long-term treatment with suberythropoietic Epo is vaso-and neuroprotective in experimental diabetic retinopathy Cellular Physiology and Biochemistry 27 6 2011 769 782
53. D. Watanabe et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy New England Journal of Medicine 353 8 2005 782 792
54. M.L. Webb, and T.D. Meek Inhibitors of endothelin Medicinal Research Reviews 17 1 1997 17 67
55. L. Wu et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Archive for Clinical and Experimental Ophthalmology 246 1 2008 81 87
56. T. Yamauchi et al. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells FEBS Letters 267 1 1990 16 18
57. J.W. Yau et al. Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 3 2011 556 564
58. L. Zhang et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control Diabetes Care 24 7 2001 1275 1279